Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant.
Esketamine
European Quality of Life Group
Five Dimension
Five Level (EQ-5D-5L)
Health-related quality of life (HRQoL)
Major depressive disorder
Sheehan Disability Scale
Treatment-resistant depression
Journal
Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626
Informations de publication
Date de publication:
08 May 2023
08 May 2023
Historique:
received:
03
11
2022
accepted:
20
03
2023
medline:
11
5
2023
pubmed:
9
5
2023
entrez:
9
5
2023
Statut:
epublish
Résumé
Patients with treatment-resistant depression (TRD) report significant deficits in physical and mental health, as well as severely impaired health-related quality of life (HRQoL) and functioning. Esketamine effectively enhances the daily functioning in these patients while also improving their depressive symptoms. This study assessed HRQoL and health status of patients with TRD, who were treated with esketamine nasal spray and an oral antidepressant (ESK + AD) vs. placebo nasal spray and an AD (AD + PBO). Data from TRANSFORM-2, a phase 3, randomized, double-blind, short-term flexibly dosed study, were analyzed. Patients (aged 18-64 years) with TRD were included. The outcome assessments included the European Quality of Life Group, Five Dimension, Five Level (EQ-5D-5L), EQ-Visual Analogue Scale (EQ-VAS), and Sheehan Disability Scale (SDS). The health status index (HSI) was calculated using EQ-5D-5L scores. The full analysis set included 223 patients (ESK + AD: 114; AD + PBO: 109; mean [SD] age: 45.7 [11.89]). At Day 28, a lower percentage of patients reported impairment in the ESK + AD vs. AD + PBO group in all five EQ-5D-5L dimensions: mobility (10.6% vs. 25.0%), self-care (13.5% vs. 32.0%), usual activities (51.9% vs. 72.0%), pain/discomfort (35.6% vs. 54.0%), and anxiety/depression (69.2% vs. 78.0%). The mean (SD) change from baseline in HSI at Day 28 was 0.310 (0.219) for ESK + AD and 0.235 (0.252) for AD + PBO, with a higher score reflecting better levels of health. The mean (SD) change from baseline in EQ-VAS score at Day 28 was greater in ESK + AD (31.1 [25.67]) vs. AD + PBO (22.1 [26.43]). The mean (SD) change in the SDS total score from baseline to Day 28 also favored ESK + AD (-13.6 [8.31]) vs. AD + PBO (-9.4 [8.43]). Greater improvements in HRQoL and health status were observed among patients with TRD treated with ESK + AD vs. AD + PBO. ClinicalTrials.gov Identifier: NCT02418585.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with treatment-resistant depression (TRD) report significant deficits in physical and mental health, as well as severely impaired health-related quality of life (HRQoL) and functioning. Esketamine effectively enhances the daily functioning in these patients while also improving their depressive symptoms. This study assessed HRQoL and health status of patients with TRD, who were treated with esketamine nasal spray and an oral antidepressant (ESK + AD) vs. placebo nasal spray and an AD (AD + PBO).
METHODS
METHODS
Data from TRANSFORM-2, a phase 3, randomized, double-blind, short-term flexibly dosed study, were analyzed. Patients (aged 18-64 years) with TRD were included. The outcome assessments included the European Quality of Life Group, Five Dimension, Five Level (EQ-5D-5L), EQ-Visual Analogue Scale (EQ-VAS), and Sheehan Disability Scale (SDS). The health status index (HSI) was calculated using EQ-5D-5L scores.
RESULTS
RESULTS
The full analysis set included 223 patients (ESK + AD: 114; AD + PBO: 109; mean [SD] age: 45.7 [11.89]). At Day 28, a lower percentage of patients reported impairment in the ESK + AD vs. AD + PBO group in all five EQ-5D-5L dimensions: mobility (10.6% vs. 25.0%), self-care (13.5% vs. 32.0%), usual activities (51.9% vs. 72.0%), pain/discomfort (35.6% vs. 54.0%), and anxiety/depression (69.2% vs. 78.0%). The mean (SD) change from baseline in HSI at Day 28 was 0.310 (0.219) for ESK + AD and 0.235 (0.252) for AD + PBO, with a higher score reflecting better levels of health. The mean (SD) change from baseline in EQ-VAS score at Day 28 was greater in ESK + AD (31.1 [25.67]) vs. AD + PBO (22.1 [26.43]). The mean (SD) change in the SDS total score from baseline to Day 28 also favored ESK + AD (-13.6 [8.31]) vs. AD + PBO (-9.4 [8.43]).
CONCLUSIONS
CONCLUSIONS
Greater improvements in HRQoL and health status were observed among patients with TRD treated with ESK + AD vs. AD + PBO.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov Identifier: NCT02418585.
Identifiants
pubmed: 37158911
doi: 10.1186/s12955-023-02113-1
pii: 10.1186/s12955-023-02113-1
pmc: PMC10169482
doi:
Substances chimiques
Esketamine
50LFG02TXD
Nasal Sprays
0
Antidepressive Agents
0
Banques de données
ClinicalTrials.gov
['NCT02418585']
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
40Informations de copyright
© 2023. Janssen Research & Development, LLC.
Références
JAMA. 1999 Nov 10;282(18):1737-44
pubmed: 10568646
Int J Neuropsychopharmacol. 2019 Oct 1;22(10):616-630
pubmed: 31290965
JAMA Psychiatry. 2018 Feb 1;75(2):139-148
pubmed: 29282469
J Affect Disord. 2019 Jan 1;242:195-210
pubmed: 30195173
Can J Psychiatry. 2019 Jun;64(6):380-387
pubmed: 30763119
Value Health. 2011 Jul-Aug;14(5):732-9
pubmed: 21839412
J Affect Disord. 2021 Mar 15;283:115-122
pubmed: 33545659
Psychiatry Res. 2020 Nov;293:113376
pubmed: 32818917
Med Care. 2016 Jan;54(1):98-105
pubmed: 26492214
BMC Psychiatry. 2018 Oct 29;18(1):352
pubmed: 30373547
Biol Psychiatry. 2003 Apr 15;53(8):649-59
pubmed: 12706951
Int J Psychiatry Med. 1997;27(2):93-105
pubmed: 9565717
Psychiatr Serv. 2014 Aug 1;65(8):977-87
pubmed: 24789696
BMJ Open. 2017 Mar 30;7(3):e015266
pubmed: 28363932
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Clin Ther. 2013 Apr;35(4):512-22
pubmed: 23490291
JAMA Psychiatry. 2019 Sep 1;76(9):893-903
pubmed: 31166571
P T. 2019 Jun;44(6):340-375
pubmed: 31160868
J Manag Care Spec Pharm. 2018 Mar;24(3):226-236
pubmed: 29485948
Qual Life Res. 2005 Aug;14(6):1523-32
pubmed: 16110932
Adv Pharmacol. 2020;89:237-259
pubmed: 32616208
J Clin Psychiatry. 2016 Feb;77 Suppl 1:4-8
pubmed: 26829431
J Clin Psychiatry. 2020 May 26;81(4):
pubmed: 32459407
J Clin Psychiatry. 2018 Mar/Apr;79(2):
pubmed: 29474009
J Affect Disord. 2021 Feb 15;281:767-775
pubmed: 33261932
Med Decis Making. 2006 Jul-Aug;26(4):410-20
pubmed: 16855129
Expert Rev Neurother. 2019 Oct;19(10):899-911
pubmed: 31282772
Int Clin Psychopharmacol. 2008 Mar;23(2):70-83
pubmed: 18301121
J Affect Disord. 2018 Aug 1;235:362-367
pubmed: 29665520
JAMA Psychiatry. 2018 Apr 1;75(4):336-346
pubmed: 29450462
Acta Psychiatr Scand. 2021 Mar;143(3):253-263
pubmed: 33249552
Int Clin Psychopharmacol. 1996 Jun;11 Suppl 3:89-95
pubmed: 8923116
Neuropsychiatr Dis Treat. 2020 Jan 21;16:221-234
pubmed: 32021216
J Clin Psychiatry. 2002 Aug;63(8):717-26
pubmed: 12197453
Psychiatry Res. 1999 Nov 29;88(3):173-89
pubmed: 10622339
Am J Psychiatry. 2006 Nov;163(11):1905-17
pubmed: 17074942
Pharmacoeconomics. 2004;22(6):363-73
pubmed: 15099122
Dialogues Clin Neurosci. 2015 Jun;17(2):111-26
pubmed: 26246787
Int Clin Psychopharmacol. 2009 May;24(3):133-8
pubmed: 19318972
Health Qual Life Outcomes. 2007 Dec 21;5:70
pubmed: 18154669
Gen Hosp Psychiatry. 2004 Jan-Feb;26(1):13-7
pubmed: 14757297
Am J Psychiatry. 2019 Jun 1;176(6):428-438
pubmed: 31109201